Allianz Asset Management Gmb H Kodiak Sciences Inc. Transaction History

Allianz Asset Management Gmb H

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	BUY	$80.85 - $128.49 $210,129 - $333,945	2,599 Added 13.22%	22,266 $1.9 Million
Q3 2021 Nov 10, 2021	BUY	$81.97 - $106.94 $16,312 - $21,281	199 Added 1.02%	19,667 $1.89 Million
Q2 2021 Aug 16, 2021	SELL	$77.2 - $126.54 $1.29 Million - $2.12 Million	-16,735 Reduced 46.23%	19,468 $1.81 Million
Q1 2021 May 13, 2021	BUY	$110.45 - $164.47 $553,133 - $823,665	5,008 Added 16.05%	36,203 $4.11 Million
Q4 2020 Feb 16, 2021	SELL	$60.78 - $154.03 $1.49 Million - $3.77 Million	-24,490 Reduced 43.98%	31,195 $4.58 Million
Q3 2020 Nov 13, 2020	SELL	$45.05 - $59.27 $108,345 - $142,544	-2,405 Reduced 4.14%	55,685 $3.3 Million
Q2 2020 Aug 14, 2020	BUY	$42.74 - $66.25 $514,803 - $797,981	12,045 Added 26.16%	58,090 $3.14 Million
Q1 2020 May 14, 2020	BUY	$38.18 - $73.95 $1.76 Million - $3.41 Million	46,045 New	46,045 $2.2 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.